

KERYX BIOPHARMACEUTICALS INC  
 Form 4  
 December 11, 2006

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 WEISS MICHAEL S

(Last) (First) (Middle)

C/O KERYX  
 BIOPHARMACEUTICALS,  
 INC., 750 LEXINGTON AVE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 KERYX  
 BIOPHARMACEUTICALS INC  
 [KERX]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 12/07/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chairman and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/07/2006		M		53,435	A	\$ 1.3
Common Stock	12/07/2006		S <sup>(1)</sup>		2,889	D	\$ 15
Common Stock	12/07/2006		S <sup>(1)</sup>		1,646	D	\$ 14.96
Common Stock	12/07/2006		S <sup>(1)</sup>		7,600	D	\$ 14.73

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

Common Stock	12/07/2006	<u>S</u> (1)	5,000	D	\$ 14.6	51,300	D
Common Stock	12/07/2006	<u>S</u> (1)	781	D	\$ 14.58	50,519	D
Common Stock	12/07/2006	<u>S</u> (1)	1,154	D	\$ 14.55	49,365	D
Common Stock	12/07/2006	<u>S</u> (1)	2,000	D	\$ 14.53	47,365	D
Common Stock	12/07/2006	<u>S</u> (1)	4,000	D	\$ 14.52	43,365	D
Common Stock	12/07/2006	<u>S</u> (1)	6,365	D	\$ 14.51	37,000	D
Common Stock	12/07/2006	<u>S</u> (1)	19,500	D	\$ 14.5	17,500	D
Common Stock	12/07/2006	<u>S</u> (1)	2,500	D	\$ 14.49	15,000	D
Common Stock	12/08/2006	M	27,102	A	\$ 1.3	42,102	D
Common Stock	12/08/2006	<u>S</u> (1)	1,000	D	\$ 14.7	41,102	D
Common Stock	12/08/2006	<u>S</u> (1)	1,000	D	\$ 14.67	40,102	D
Common Stock	12/08/2006	<u>S</u> (1)	2,000	D	\$ 14.65	38,102	D
Common Stock	12/08/2006	<u>S</u> (1)	2,000	D	\$ 14.64	36,102	D
Common Stock	12/08/2006	<u>S</u> (1)	1,000	D	\$ 14.63	35,102	D
Common Stock	12/08/2006	<u>S</u> (1)	1,000	D	\$ 14.62	34,102	D
Common Stock	12/08/2006	<u>S</u> (1)	3,000	D	\$ 14.61	31,102	D
Common Stock	12/08/2006	<u>S</u> (1)	7,255	D	\$ 14.6	23,847	D
Common Stock	12/08/2006	<u>S</u> (1)	2,000	D	\$ 14.58	21,847	D
Common Stock	12/08/2006	<u>S</u> (1)	2,500	D	\$ 14.55	19,347	D
Common Stock	12/08/2006	<u>S</u> (1)	4,347	D	\$ 14.49	15,000	D
	12/11/2006	M	22,895	A	\$ 1.3	37,895	D

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

Common Stock							
Common Stock	12/11/2006	S <sup>(1)</sup>	1,000	D	\$ 14.68	36,895	D
Common Stock	12/11/2006	S <sup>(1)</sup>	1,000	D	\$ 14.6	35,895	D
Common Stock	12/11/2006	S <sup>(1)</sup>	395	D	\$ 14.56	35,500	D
Common Stock	12/11/2006	S <sup>(1)</sup>	1,000	D	\$ 14.54	34,500	D
Common Stock	12/11/2006	S <sup>(1)</sup>	1,000	D	\$ 14.53	33,500	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	\$ 1.3	12/07/2006		M	53,435 (2)	12/23/2003 <sup>(3)</sup>	12/24/2012	Common Stock	53,435
Options (Right to Buy)	\$ 1.3	12/08/2006		M	27,102 (2)	12/23/2003 <sup>(3)</sup>	12/24/2012	Common Stock	27,102
Options (Right to Buy)	\$ 1.3	12/11/2006		M	22,895 (2)	12/23/2003 <sup>(3)</sup>	12/24/2012	Common Stock	22,895

## Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

Director    10% Owner    Officer    Other

WEISS MICHAEL S  
C/O KERYX BIOPHARMACEUTICALS, INC.  
750 LEXINGTON AVE  
NEW YORK, NY 10022

X

Chairman and CEO

## Signatures

/s/ Ronald C. Renaud Jr.,  
Attorney-in-Fact

12/11/2006

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Shares of Common Stock were sold pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated August 8, 2006.
- (2) The options were exercised pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated August 8, 2006.
- (3) All options have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.